Pharma Business - June 5, 2026
Diamyd Medical provides business update
As part of an ongoing strategic review, the company has received several proposals from external parties, including formal non-binding Letters of Intent, as well as invitations to invest into various business opportunities, it states.
Pharma Business - May 29, 2026
Sunresin to open new European site in Uppsala
The Uppsala site has been established to support scientific collaboration, application development and resin innovation.
Agreement - May 26, 2026
Oncopeptides signs agreement with Salus
The agreement for distribution and commercialization of Pepaxti in Central and Eastern Europe addresses a market potential of approximately SEK 150 million and enables potential sales uptake in this region earlier than previously planned, the company states.
New Market - May 20, 2026
Lundbeck receives orphan drug designation in Japan
The orphan drug designation has been granted for asedebart for the treatment of patients with congenital adrenal hyperplasia and Cushing’s disease.
CDMO - May 20, 2026
Diamyd Medical receives GMP certification and manufacturing authorization
The company has now received GMP (Good Manufacturing Practice) certification as well as manufacturing authorization from the Swedish Medical Products Agency for the production of biological investigational medicinal products for human use.
Collaboration - May 20, 2026
Herantis Pharma partners with Indivi
Herantis Pharma has announced a collaboration with Indivi, a Basel-based TechBio company focused on advancing precision medicine in neuroscience drug development, to integrate Indivi's digital biomarker platform into Herantis' upcoming Phase 2 proof-of-concept study of HER-096 in people living with Parkinson's disease.